Promisia along with other companies that use Artemisia Annua, made submissions challenging the proposed reclassification and recommending that Artemisia Annua should remain a dietary supplement. The company is unaware of any other natural product being classified as a prescription medicine in New Zealand. The Classification Committee met in October 2019 and, to the surprise of the natural products sector, made a recommendation to the Minister of Health that Artemisia Annua was to be reclassified as a prescription only medicine. This recommendation was appealed by Promisia and a number of other companies. All appeals were rejected and the reclassification will come into effect on 4 March 2020. The company is aware that at least one party is intending to apply for a judicial review of the decision process, the final decision and the recommendation to the Minister. The final decision of the Medicines Classification Committee confirms that the decision to exit the natural products market was correct. This decision will have minimal impact on Promisia as most stock was written off as at 30 June 2019 and the stock retained has been sold.